Terreni Eleonora, Zucchetti Erica, Tampucci Silvia, Burgalassi Susi, Monti Daniela, Chetoni Patrizia
Department of Pharmacy, University of Pisa, Via Bonanno 33, 56126 Pisa, Italy.
Centro 3R (Inter-University Center for the Promotion of the 3Rs Principles in Teaching & Research), 56122 Pisa, Italy.
Pharmaceutics. 2021 Feb 1;13(2):192. doi: 10.3390/pharmaceutics13020192.
A combination of in situ gelling systems and a loaded drug self-assembling nanomicellar carrier was chosen in this study as a new potential Ocular Drug Delivery System (ODDS) for Cyclosporine-A (CyA), a poorly water-soluble drug. Two non-ionic surfactants (d-α-tocopherol polyethylene glycol succinate, VitE-TPGS and polyoxyl 40 hydrogenated castor oil, RH-40) were used to produce the nanomicelles. The physical-chemical characterization of the nanomicelles in terms of CyA entrapment (EE%) and loading efficiency (LE%), cloud point (CP), regeneration time (RT), size and polydispersity index (PI) allowed us to select the best combination of surfactant mixture, which showed appropriate stability, high CyA-EE (99.07%), very small and homogeneous dimensions and favored the solubilization of an amount of CyA (0.144% /) comparable to that contained in marketed emulsion Ikervis. The selected nanomicellar formulation incorporated into optimized ion-sensitive polymeric dispersions of gellan gum (GG-LA: 0.10, 0.15 and 0.20% /) able to trigger the sol-gel transition after instillation was characterized from technological (osmolality, pH, gelling capacity, rheological behavior, wettability, TEM and storage stability at 4 and 20 °C) and biopharmaceutical points of view. This new combined approach allowed us to obtain clear aqueous dispersions that were easy to instill and able to form a viscous gel when in contact with the tear fluid, improving CyA ocular bioavailability. Furthermore, this new ODDS prevented CyA transcorneal permeation, exhibited low cytotoxicity and prolonged the CyA resident time in the precorneal area compared to Ikervis.
本研究选择原位凝胶系统与载药自组装纳米胶束载体相结合,作为一种新的潜在眼用药物递送系统(ODDS)用于环孢素A(CyA),这是一种水溶性差的药物。使用两种非离子表面活性剂(d-α-生育酚聚乙二醇琥珀酸酯,维生素E-TPGS和聚氧乙烯40氢化蓖麻油,RH-40)制备纳米胶束。通过对纳米胶束的物理化学表征,包括CyA包封率(EE%)、载药效率(LE%)、浊点(CP)、再生时间(RT)、粒径和多分散指数(PI),使我们能够选择最佳的表面活性剂混合物组合,该组合表现出适当的稳定性、高CyA-EE(99.07%)、非常小且均匀的尺寸,并有利于溶解与市售乳剂Ikervis中所含CyA量相当的CyA(0.144% /)。将所选的纳米胶束制剂掺入优化的结冷胶离子敏感聚合物分散体(GG-LA:0.10、0.15和0.20% /)中,该分散体在滴注后能够引发溶胶-凝胶转变,并从技术(渗透压、pH值、胶凝能力、流变行为、润湿性、透射电子显微镜和4℃和20℃下的储存稳定性)和生物药剂学角度进行了表征。这种新的组合方法使我们能够获得易于滴注的澄清水分散体,并且在与泪液接触时能够形成粘性凝胶,从而提高CyA的眼部生物利用度。此外,与Ikervis相比,这种新的ODDS可防止CyA经角膜渗透,具有低细胞毒性并延长了CyA在角膜前区的停留时间。